Zura Bio Limited (NASDAQ:ZURA) Receives Average Rating of “Buy” from Analysts

Zura Bio Limited (NASDAQ:ZURA) has been given a consensus rating of “Buy” by the six ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $16.75.

ZURA has been the subject of a number of research analyst reports. HC Wainwright reiterated a “neutral” rating and set a $5.00 price target on shares of Zura Bio in a report on Monday, October 21st. Leerink Partners assumed coverage on Zura Bio in a report on Monday, November 4th. They set an “outperform” rating and a $15.00 target price on the stock. Piper Sandler restated an “overweight” rating and issued a $26.00 price target on shares of Zura Bio in a research note on Thursday, September 19th. Leerink Partnrs raised shares of Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a research report on Friday, October 18th.

Zura Bio Stock Performance

Shares of NASDAQ ZURA opened at $4.58 on Tuesday. Zura Bio has a fifty-two week low of $2.00 and a fifty-two week high of $6.35. The business has a 50-day moving average of $4.18 and a 200-day moving average of $4.11.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Research analysts anticipate that Zura Bio will post -0.49 EPS for the current fiscal year.

Insider Buying and Selling

In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of the stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total transaction of $200,187.36. Following the transaction, the director now owns 2,085,418 shares in the company, valued at $8,070,567.66. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 22.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ZURA. AQR Capital Management LLC bought a new stake in Zura Bio during the second quarter worth about $43,000. Renaissance Technologies LLC boosted its holdings in shares of Zura Bio by 51.3% in the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after purchasing an additional 5,900 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Zura Bio during the 3rd quarter worth $62,000. Forefront Analytics LLC lifted its position in shares of Zura Bio by 22.1% during the 2nd quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock worth $145,000 after buying an additional 7,531 shares during the last quarter. Finally, Palumbo Wealth Management LLC bought a new position in Zura Bio in the third quarter valued at about $156,000. 61.14% of the stock is owned by institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.